Table 1

Patients characteristics

Total
N=1650
TR 0
N=232
TR 1
N=1053
TR 2
N=287
TR 3
N=78
P value
Mean±SD or %Mean±SD or %Mean±SD or %Mean±SD or %Mean±SD or %
Age in years73.2±10.970.6±12.873.0±10.875.7±9.374.5±9.9<0.001
Female gender42.837.540.950.755.10.001
BMI (kg/m2)27.9±5.129.8±5.527.9±4.926.7±5.126.9±5.0<0.001
CV risk factors
 Hypertension92.791.793.092.393.50.892
 Dyslipidaemia69.873.271.364.758.40.013
Comorbidities general
 Diabetes mellitus33.538.331.435.339.00.107
 CKD (eGFR <60 mL/min)45.632.644.256.861.5<0.001
 COPD15.512.314.818.523.40.051
Comorbidities cardiac
 Pulmonary hypertension
  Unlikely*51.588.853.018.142.3<0.001
  Possible*26.16.528.233.428.2
  Likely*22.54.718.848.429.5
 Atrial fibrillation48.325.944.770.380.5<0.001
 DCM10.76.610.813.013.00.109
 Coronary artery disease57.957.859.853.848.10.089
 Aortic stenosis (at least moderate)19.520.321.513.911.5<0.001
 Prior aortic valve replacement9.110.38.211.87.70.226
 Mitral regurgitation (at least moderate)18.83.013.853.254.9<0.001
 Prior mitral valve replacement/repair4.62.63.88.09.00.003
 Prior cardiac device22.610.521.532.935.1<0.001
Laboratory results
 NT-proBNP (n=995)3610±47661264±17833461±46955264±50256209±6689<0.001
 CKD-EPI GFR (ml/min) (n=1244)64.4±27.171.0±29.365.6±26.456.4±27.055.5±21.3<0.001
  • Bold values denote statistical significance at the p≤0.05 level.

  • *The probability of pulmonary hypertension was estimated by the peak tricuspid regurgitation velocity and graded according to European Society of Cardiology guidelines.17 18

  • BMI, body mass index; CV, cardiovascular; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; COPD, chronic obstructive pulmonary disease; DCM, dilative cardiomyopathy; NT-proBNP, N-terminal pro brain natriuretic peptide.;